Richard Saynor, Sandoz CEO
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Novartis’ generics giant Sandoz has been in the biosimilars space since the very beginning, and as uptake has stalled even in more developed markets like …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
